4.0 Review

SGLT2 inhibitors and the kidney: Effects and mechanisms

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.dsx.2018.06.003

关键词

Key words; Sodium glucose cotransporter 2; Kidney; Nephroprotection; Acute kidney injury; Ketones

资金

  1. Astra-Zeneca
  2. Bristol-Myers Squibb
  3. Pfizer
  4. Lilly
  5. Abbott
  6. Amgen
  7. AstraZeneca
  8. Novartis
  9. Vianex
  10. Teva
  11. MSD
  12. Sanofi-Aventis
  13. Boehringer Ingelheim
  14. Eli-Lilly
  15. GSK

向作者/读者索取更多资源

Aims: Numerous clinical trials have shown that sodium glucose cotransporter 2 (SGLT2) inhibitors exert a favorable effect on the indices of renal function (albuminuria, glomerular filtration rate decline over time) and the incidence of hard renal endpoints such as renal death or time to initiation of renal replacement therapy. Materials and methods: In this review, we describe in detail the evidence regarding the nephroprotective mechanisms of SGLT2 inhibitors and describe the risk factors that may predispose to the development of acute kidney injury in patients receiving these drugs. Results: Although the impact of these drugs on renal hemodynamics seems to represent the most important renoprotective mechanism of action, many other effects of these compounds, including beneficial effects on metabolism and blood pressure, have been proposed to contribute to the observed clinical benefit. Conclusions: SGLT2 inhibitors clearly act beneficially in terms of kidney function with many proposed mechanisms. (c) 2018 Diabetes India. Published by Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.0
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据